<- Go Home
Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Market Cap
GBP 29.7B
Volume
23.1M
Cash and Equivalents
GBP 1.3B
EBITDA
GBP 2.7B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 7.1B
Profit Margin
64.77%
52 Week High
GBP 4.20
52 Week Low
GBP 2.74
Dividend
2.13%
Price / Book Value
1.81
Price / Earnings
18.05
Price / Tangible Book Value
-3.24
Enterprise Value
GBP 37.0B
Enterprise Value / EBITDA
13.24
Operating Income
GBP 2.5B
Return on Equity
10.27%
Return on Assets
4.67
Cash and Short Term Investments
GBP 1.4B
Debt
GBP 8.6B
Equity
GBP 16.5B
Revenue
GBP 11.0B
Unlevered FCF
GBP 1.6B
Sector
Pharmaceuticals
Category
N/A